Dazoxiben (BioDeep_00000177977)

   

human metabolite blood metabolite


代谢物信息卡片


4-(2-(1H-Imidazol-1-yl)ethoxy)benzoic acid hydrochloride

化学式: C12H12N2O3 (232.0847882)
中文名称: 达唑氧苯
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=CC(=CC=C1C(=O)O)OCCN2C=CN=C2
InChI: InChI=1S/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)

描述信息

C78275 - Agent Affecting Blood or Body Fluid > C29750 - Thrombolytic Agent
D004791 - Enzyme Inhibitors

同义名列表

5 个代谢物同义名

4-(2-(1H-Imidazol-1-yl)ethoxy)benzoic acid hydrochloride; 4-[2-(1H-imidazol-1-yl)ethoxy]benzoic acid; 4-[2-(1H-Imidazol-1-yl)ethoxy]benzoate; Dazoxiben hydrochloride; Dazoxiben



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
  • Meng Tao Zhou, Bi Cheng Chen, Hong Wei Sun, Yue Peng Jin, Fa Jing Yang, Xing Zhang, Roland Andersson, Qi Yu Zhang. Continuous regional arterial infusion with fluorouracil and octreotide attenuates severe acute pancreatitis in a canine model. PloS one. 2012; 7(5):e37347. doi: 10.1371/journal.pone.0037347. [PMID: 22655040]
  • E M Shapovalova, A J Rudzevich. Effect of inhibitors of arachidonic acid conversion in platelets on thrombin-fibrinogen interaction and thrombin tolerance. Bulletin of experimental biology and medicine. 2007 Oct; 144(4):527-8. doi: 10.1007/s10517-007-0368-4. [PMID: 18642704]
  • Cristiane F Freitas, Renato Faro, Desanka Dragosavac, Martine Clozel, Gilberto De Nucci, Edson Antunes. Role of endothelin-1 and thromboxane A2 in the pulmonary hypertension induced by heparin-protamine interaction in anesthetized dogs. Journal of cardiovascular pharmacology. 2004 Jan; 43(1):106-12. doi: 10.1097/00005344-200401000-00016. [PMID: 14668575]
  • Sandra L Pfister, Miranda J Hughes, Mark Rosolowsky, William B Campbell. Role of contaminating platelets in thromboxane synthesis in primary cultures of human umbilical vein endothelial cells. Prostaglandins & other lipid mediators. 2002 Sep; 70(1-2):39-49. doi: 10.1016/s0090-6980(02)00009-6. [PMID: 12428677]
  • Roberta Vezza, Anna Maria Mezzasoma, Gigliola Venditti, Paolo Gresele. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thrombosis and haemostasis. 2002 Jan; 87(1):114-21. doi: 10.1055/s-0037-1612953. [PMID: 11848439]
  • R W Hartmann, M Hector, B G Wachall, A Palusczak, M Palzer, V Huch, M Veith. Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17alpha-hydroxylase/C17-20-lyase (P450 17). Journal of medicinal chemistry. 2000 Nov; 43(23):4437-45. doi: 10.1021/jm991070n. [PMID: 11087568]
  • R W Hartmann, M Hector, S Haidar, P B Ehmer, W Reichert, J Jose. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2. Journal of medicinal chemistry. 2000 Nov; 43(22):4266-77. doi: 10.1021/jm001008m. [PMID: 11063622]
  • C Jacobs, M Frotscher, G Dannhardt, R W Hartmann. 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase. Journal of medicinal chemistry. 2000 May; 43(9):1841-51. doi: 10.1021/jm991180u. [PMID: 10794700]
  • M H Carvalho, Z B Fortes, D Nigro, M A Oliveira, R Scivoletto. The role of thromboxane A2 in the altered microvascular reactivity in two-kidney, one-clip hypertension. Endothelium : journal of endothelial cell research. 1997; 5(3):167-78. doi: 10.3109/10623329709053396. [PMID: 9272380]
  • W T de Lima, F H Kwasniewski, P Sirois, S Jancar. Studies on the mechanism of PAF-induced vasopermeability in rat lungs. Prostaglandins, leukotrienes, and essential fatty acids. 1995 Apr; 52(4):245-9. doi: 10.1016/0952-3278(95)90044-6. [PMID: 7784472]
  • R J Gryglewski, A Szczeklik, R Korbut, J Swies, J Musiał, M Krzanowski, P Maga. The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel--a new thromboxane synthase inhibitor. Wiener klinische Wochenschrift. 1995; 107(9):283-9. doi: NULL. [PMID: 7778318]
  • L Oleksowicz, Z Mrowiec, D Zuckerman, R Isaacs, J Dutcher, E Puszkin. Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism. Thrombosis and haemostasis. 1994 Aug; 72(2):302-8. doi: . [PMID: 7831669]
  • W Yuan. [Changes in renal cortical thromboxane A2, prostaglandin F1 alpha and effects of dazoxiben, chuan xiong on in situ immune complex glomerulonephritis in rats]. Zhonghua yi xue za zhi. 1993 Sep; 73(9):528-31, 574. doi: NULL. [PMID: 8313194]
  • N Ohara, N F Voelkel, S W Chang. Tissue eicosanoids and vascular permeability in rats with chronic biliary obstruction. Hepatology (Baltimore, Md.). 1993 Jul; 18(1):111-8. doi: 10.1002/hep.1840180118. [PMID: 8325602]
  • M Tuncer, P M Vanhoutte. Serotonin releases a vasoconstrictor prostanoid in the kidney of the aging spontaneously hypertensive rat. Blood pressure. 1993 Jun; 2(2):142-5. doi: 10.3109/08037059309077542. [PMID: 8180727]
  • P Golino, G Ambrosio, B Villari, M Ragni, A Focaccio, L Pace, F de Clerk, M Condorelli, M Chiariello. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion. Journal of the American College of Cardiology. 1993 Feb; 21(2):493-501. doi: 10.1016/0735-1097(93)90694-v. [PMID: 8426016]
  • M F Bureau, F De Clerck, J Lefort, C D Arreto, B B Vargaftig. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung. The Journal of pharmacology and experimental therapeutics. 1992 Feb; 260(2):832-40. doi: NULL. [PMID: 1738127]
  • S S Bhagwat, C Gude, D S Cohen, W Lee, P Furness, F H Clarke. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids. Journal of medicinal chemistry. 1991 Jun; 34(6):1790-7. doi: 10.1021/jm00110a006. [PMID: 1829485]
  • F Asai, T Ito, S Ushiyama, K Matsuda, T Oshima. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate. Arzneimittel-Forschung. 1991 May; 41(5):506-10. doi: NULL. [PMID: 1898421]
  • I S Watts, K A Wharton, B P White, P Lumley. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. British journal of pharmacology. 1991 Feb; 102(2):497-505. doi: 10.1111/j.1476-5381.1991.tb12200.x. [PMID: 1826620]
  • P Golino, M Rosolowsky, S K Yao, J McNatt, F De Clerck, L M Buja, J T Willerson. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis. The Journal of clinical investigation. 1990 Oct; 86(4):1095-102. doi: 10.1172/jci114813. [PMID: 2145320]
  • S K Yao, M Rosolowsky, H V Anderson, P Golino, J M NcNatt, F De Clerck, L M Buja, J T Willerson. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations. Journal of the American College of Cardiology. 1990 Sep; 16(3):705-13. doi: 10.1016/0735-1097(90)90363-t. [PMID: 2143767]
  • T Ito, F Asai, T Oshima, S Kobayashi. Role of activated platelets in endotoxin-induced DIC in rats. Thrombosis research. 1990 Aug; 59(4):735-47. doi: 10.1016/0049-3848(90)90055-h. [PMID: 2080492]
  • W L Salzer, C E McCall. Primed stimulation of isolated perfused rabbit lung by endotoxin and platelet activating factor induces enhanced production of thromboxane and lung injury. The Journal of clinical investigation. 1990 Apr; 85(4):1135-43. doi: 10.1172/jci114545. [PMID: 2318970]
  • J L Archibald, G Bradley, A Opalko, T J Ward, J C White, C Ennis, N B Shepperson. Design of an antithrombotic-antihypertensive agent (Wy 27569). Synthesis and evaluation of a series of 2-heteroaryl-substituted dihydropyridines. Journal of medicinal chemistry. 1990 Feb; 33(2):646-52. doi: 10.1021/jm00164a028. [PMID: 2299629]
  • R Korbut, A Ocetkiewicz, W Dabros, R J Gryglewski. A biological method for studying the interaction between platelets and vascular endothelium. Thrombosis research. 1990 Feb; 57(3):361-70. doi: 10.1016/0049-3848(90)90252-8. [PMID: 2107594]
  • Y C Rui, D X Sun, K Long. [Effect of dazoxiben on cerebrovascular resistance in rabbits]. Zhongguo yao li xue bao = Acta pharmacologica Sinica. 1989 Jul; 10(4):342-5. doi: NULL. [PMID: 2624120]
  • P Gresele, H Deckmyn, J Arnout, G G Nenci, J Vermylen. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thrombosis and haemostasis. 1989 Jun; 61(3):479-84. doi: NULL. [PMID: 2552606]
  • Y Hori, H Hatakeyama, K Yamada, A Kurosawa. Effect of a novel thromboxane A2 receptor antagonist, S-145, on collagen-induced ECG changes and thrombocytopenia in rodents. Japanese journal of pharmacology. 1989 Jun; 50(2):195-205. doi: 10.1254/jjp.50.195. [PMID: 2528013]
  • C Ennis, S E Granger, V C Middlefell, M E Philpot, N B Shepperson. Pharmacologic effects of Wy 27569: a combined calcium channel blocker and thromboxane synthetase inhibitor. Journal of cardiovascular pharmacology. 1989 Apr; 13(4):511-9. doi: . [PMID: 2470986]
  • G R Martinez, K A Walker, D R Hirschfeld, P J Maloney, D S Yang, R P Rosenkranz. [(1H-imidazol-1-yl)methyl]- and [(3-pyridinyl)methyl]pyrroles as thromboxane synthetase inhibitors. Journal of medicinal chemistry. 1989 Apr; 32(4):890-7. doi: 10.1021/jm00124a027. [PMID: 2704033]
  • T J Ferro, A Johnson, J Everitt, A B Malik. IL-2 induces pulmonary edema and vasoconstriction independent of circulating lymphocytes. Journal of immunology (Baltimore, Md. : 1950). 1989 Mar; 142(6):1916-21. doi: NULL. [PMID: 2784141]
  • W Hornberger, H Patscheke. Transient concentrations and agonist potency of PGH2 in platelet activation by endogenous arachidonate. Eicosanoids. 1989; 2(4):241-8. doi: . [PMID: 2517034]
  • R Vanholder, G Laekeman, A Herman, B Saragananda, M A Waterloos, D Kesteloot, N Lámeire. The inhibition of thromboxane synthesis has no influence on HgCl2-induced acute renal failure in the rat. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 1989; 4(7):625-31. doi: . [PMID: 2510059]
  • M Narisada, M Ohtani, F Watanabe, K Uchida, H Arita, M Doteuchi, K Hanasaki, H Kakushi, K Otani, S Hara. Synthesis and in vitro activity of various derivatives of a novel thromboxane receptor antagonist, (+/-)-(5Z)-7-[3-endo-[(phenylsulfonyl)amino]bicyclo[2.2.1] hept-2-exo-yl]heptenoic acid. Journal of medicinal chemistry. 1988 Sep; 31(9):1847-54. doi: 10.1021/jm00117a028. [PMID: 2970551]
  • R Winn, B Enderson, S Price, C L Rice. Indomethacin, but not dazoxiben, reduced lung fluid filtration after E. coli infusion. Journal of applied physiology (Bethesda, Md. : 1985). 1988 Jun; 64(6):2468-73. doi: 10.1152/jappl.1988.64.6.2468. [PMID: 3042734]
  • R Garcia-Szabo, A Johnson, A B Malik. Thromboxane increases pulmonary vascular resistance and transvascular fluid and protein exchange after pulmonary microembolism. Prostaglandins. 1988 May; 35(5):707-21. doi: 10.1016/0090-6980(88)90144-x. [PMID: 3399679]
  • B van Ooijen, R J Ouwendijk, W J Kort, F J Zijlstra, J E Vincent, J H Wilson, D L Westbroek. Raised plasma thromboxane B2 levels in experimental acute necrotizing pancreatitis in rats. The effects of flunarizine, dazoxiben, and indomethacin. Scandinavian journal of gastroenterology. 1988 Mar; 23(2):188-92. doi: 10.3109/00365528809103966. [PMID: 3363291]
  • P Gresele, J Arnout, H Deckmyn, E Huybrechts, G Pieters, J Vermylen. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. The Journal of clinical investigation. 1987 Nov; 80(5):1435-45. doi: 10.1172/jci113223. [PMID: 2960694]
  • R Naeije, R Hallemans, C Melot, J M Boeynaems, P Mols, P Lejeune, M A Rie. Eicosanoids and hypoxic pulmonary vasoconstriction in normal man. Bulletin europeen de physiopathologie respiratoire. 1987 Nov; 23(6):613-7. doi: NULL. [PMID: 3453756]
  • R Korbut, A Dembińska-Kieć, J Swies, A Zmuda, R J Gryglewski. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors. Thrombosis and haemostasis. 1987 Oct; 58(3):827-30. doi: 10.1055/s-0038-1645998. [PMID: 3324381]
  • R W Olson, D S Cohen, E C Ku, E F Kimble, H B Renfroe, E F Smith. CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben. European journal of pharmacology. 1987 Jan; 133(3):265-73. doi: 10.1016/0014-2999(87)90022-7. [PMID: 3104066]
  • R Vanholder, G Laekman, A Herman, N Lámeire. Influence of vasoactive substances on early toxic acute renal failure in the dog. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 1987; 2(5):332-40. doi: NULL. [PMID: 3122111]
  • K F Badr, V E Kelley, H G Rennke, B M Brenner. Roles for thromboxane A2 and leukotrienes in endotoxin-induced acute renal failure. Kidney international. 1986 Oct; 30(4):474-80. doi: 10.1038/ki.1986.210. [PMID: 3537451]
  • A C Honey, N Lad, D P Tuffin. Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit. Thrombosis and haemostasis. 1986 Aug; 56(1):80-5. doi: . [PMID: 3775692]
  • S Price, J Harlan, C J Carrico, J Hildebrandt, R Winn. Indomethacin, dazoxiben and extravascular lung water after Escherichia coli infusion. The Journal of surgical research. 1986 Aug; 41(2):189-97. doi: 10.1016/0022-4804(86)90024-7. [PMID: 3093772]
  • L A Lindsay, R W Olson, Y Sakane, R Ghai, E F Smith. Dazoxiben, UK 38,485 and aspirin: duration of effect for preventing thrombotic sudden death in rabbits. Thrombosis research. 1986 Jul; 43(2):177-86. doi: 10.1016/0049-3848(86)90058-7. [PMID: 3090734]
  • T Sills, S Heptinstall. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour. Thrombosis and haemostasis. 1986 Jun; 55(3):305-8. doi: 10.1055/s-0038-1661552. [PMID: 3018954]
  • H Sandler, B Gerdin, T Saldeen. Studies on the role of thromboxane in thrombin-induced pulmonary insufficiency in the rat. Thrombosis research. 1986 Apr; 42(2):165-75. doi: 10.1016/0049-3848(86)90292-6. [PMID: 3754987]
  • T Sills, A J Cowley, S Heptinstall. Aspirin and dazoxiben as inhibitors of platelet behaviour: modification of their effects by agents that alter cAMP production. Thrombosis research. 1986 Apr; 42(1):91-8. doi: 10.1016/0049-3848(86)90200-8. [PMID: 3010495]
  • T C Noonan, A B Malik. Pulmonary vascular response to leukotriene D4 in unanesthetized sheep: role of thromboxane. Journal of applied physiology (Bethesda, Md. : 1985). 1986 Mar; 60(3):765-9. doi: 10.1152/jappl.1986.60.3.765. [PMID: 3957828]
  • P E Klotman, S R Smith, B D Volpp, T M Coffman, W E Yarger. Thromboxane synthetase inhibition improves function of hydronephrotic rat kidneys. The American journal of physiology. 1986 Feb; 250(2 Pt 2):F282-7. doi: 10.1152/ajprenal.1986.250.2.f282. [PMID: 3456211]
  • M H Gee, S Z Perkowski, M V Tahamont, J T Flynn, M A Wasserman. Thromboxane as a mediator of pulmonary dysfunction during intravascular complement activation in sheep. The American review of respiratory disease. 1986 Feb; 133(2):269-73. doi: 10.1164/arrd.1986.133.2.269. [PMID: 3753832]
  • H H Oei, H C Zoganas, Y Sakane, R D Robson, T M Glenn. Inhibition of thromboxane biosynthesis in splanchnic ischemia shock. Circulatory shock. 1986; 18(2):95-106. doi: NULL. [PMID: 3753907]
  • H Bounameaux, P Gresele, M Hanss, F De Cock, J Vermylen, D Collen. Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. Thrombosis research. 1985 Oct; 40(2):161-70. doi: 10.1016/0049-3848(85)90326-3. [PMID: 3934784]
  • M A Orchard, K A Waddell, P J Lewis, I A Blair. Thromboxane synthase inhibition causes re-direction of prostaglandin endoperoxides to prostaglandin D2 during collagen stimulated aggregation of human platelet rich plasma. Thrombosis research. 1985 Sep; 39(6):701-10. doi: 10.1016/0049-3848(85)90254-3. [PMID: 3936223]
  • N C Partridge, C J Hillyard, R D Nolan, T J Martin. Regulation of prostaglandin production by osteoblast-rich calvarial cells. Prostaglandins. 1985 Sep; 30(3):527-39. doi: 10.1016/0090-6980(85)90124-8. [PMID: 3877317]
  • E F Smith, H Darius, H Ferber, K Schrör. Inhibition of thromboxane and 12-HPETE formation by dazoxiben and its two thiophenic acid-substituted derivatives. European journal of pharmacology. 1985 Jun; 112(2):161-9. doi: 10.1016/0014-2999(85)90492-3. [PMID: 3896821]
  • E Irisarri, M J Kessedjian, C Charuel, J M Faccini, P Greaves, A M Monro, J Nachbaur, Y Rabémampianina. Dazoxiben, a prototype inhibitor of thromboxane synthesis, has little toxicity in laboratory animals. Human toxicology. 1985 May; 4(3):311-5. doi: 10.1177/096032718500400312. [PMID: 4040117]
  • H Patscheke. Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid. Biochemical pharmacology. 1985 Apr; 34(8):1151-6. doi: 10.1016/0006-2952(85)90488-5. [PMID: 3922373]
  • H D Reines, P V Halushka, L S Olanoff, P S Hunt. Dazoxiben in human sepsis and adult respiratory distress syndrome. Clinical pharmacology and therapeutics. 1985 Apr; 37(4):391-5. doi: 10.1038/clpt.1985.60. [PMID: 3979000]
  • R Malamet, R A Wise, W H Ettinger, F M Wigley. Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. The American journal of medicine. 1985 Apr; 78(4):602-8. doi: 10.1016/0002-9343(85)90402-4. [PMID: 3157318]
  • T M Coffman, W E Yarger, P E Klotman. Functional role of thromboxane production by acutely rejecting renal allografts in rats. The Journal of clinical investigation. 1985 Apr; 75(4):1242-8. doi: 10.1172/jci111822. [PMID: 3886703]
  • G Mallarkey, G M Smith. A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats. British journal of pharmacology. 1985 Feb; 84(2):425-30. doi: 10.1111/j.1476-5381.1985.tb12926.x. [PMID: 3156648]
  • F Mogensen, J B Knudsen, V Rasmussen, E Kjøller, J Gormsen. Effect of specific thromboxane-synthetase inhibition on thromboxane and prostaglandin synthesis in stable angina induced by exercise test. Thrombosis research. 1985 Jan; 37(2):259-66. doi: 10.1016/0049-3848(85)90014-3. [PMID: 4038824]
  • R D Zipser, I Kronborg, W Rector, T Reynolds, G Daskalopoulos. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome. Gastroenterology. 1984 Dec; 87(6):1228-32. doi: 10.1016/0016-5085(84)90187-2. [PMID: 6593268]
  • C Chiabrando, M N Castagnoli, A Noseda, R Fanelli, G Rajtar, C Cerletti, G de Gaetano. Comparison of radioimmunoassay and high-resolution gas chromatography mass spectrometry for the quantitative determination of serum thromboxane B2 and 6-keto-PGF1 alpha after pharmacological blockade of thromboxane synthetase. Prostaglandins, leukotrienes, and medicine. 1984 Oct; 16(1):79-88. doi: 10.1016/0262-1746(84)90088-x. [PMID: 6440153]
  • Y L Lai, W J Lamm, J Hildebrandt. Factors affecting massive postmortem bronchoconstriction in guinea pig lungs. Journal of applied physiology: respiratory, environmental and exercise physiology. 1984 Sep; 57(3):692-7. doi: 10.1152/jappl.1984.57.3.692. [PMID: 6208178]
  • J R Luderer, G G Nicholas, M M Neumyer, D L Riley, J E Vary, G Garcia, D W Schneck. Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon. Clinical pharmacology and therapeutics. 1984 Jul; 36(1):105-15. doi: 10.1038/clpt.1984.147. [PMID: 6428793]
  • P Gresele, H Deckmyn, E Huybrechts, J Vermylen. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochemical pharmacology. 1984 Jul; 33(13):2083-8. doi: 10.1016/0006-2952(84)90577-x. [PMID: 6430299]
  • V Bertelé, A Falanga, M Tomasiak, C Chiabrando, C Cerletti, G de Gaetano. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products. Blood. 1984 Jun; 63(6):1460-6. doi: NULL. [PMID: 6426554]
  • L R Bush, W B Campbell, L M Buja, G D Tilton, J T Willerson. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation. 1984 Jun; 69(6):1161-70. doi: 10.1161/01.cir.69.6.1161. [PMID: 6546902]
  • B L Furman, K McKechnie, J R Parratt. Failure of drugs that selectively inhibit thromboxane synthesis to modify endotoxin shock in conscious rats. British journal of pharmacology. 1984 May; 82(1):289-94. doi: 10.1111/j.1476-5381.1984.tb16470.x. [PMID: 6375795]
  • C Cerletti, C Chiabrando, R Fanelli, G de Gaetano. Is immunoreactive 6-keto-PGF1 alpha measured in serum after treatment with thromboxane-synthetase inhibitors an index of prostacyclin synthesis?. Lancet (London, England). 1984 Apr; 1(8383):967-8. doi: 10.1016/s0140-6736(84)92430-9. [PMID: 6143907]
  • V Bertelé, A Falanga, M Tomasiak, C Cerletti, G de Gaetano. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor. Thrombosis and haemostasis. 1984 Feb; 51(1):125-8. doi: 10.1055/s-0038-1661037. [PMID: 6326343]
  • P Patrignani, P Filabozzi, F Catella, F Pugliese, C Patrono. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism. The Journal of pharmacology and experimental therapeutics. 1984 Feb; 228(2):472-7. doi: NULL. [PMID: 6537977]
  • J A Cook, W C Wise, R R Butler, H D Reines, W Rambo, P V Halushka. The potential role of thromboxane and prostacyclin in endotoxic and septic shock. The American journal of emergency medicine. 1984 Jan; 2(1):28-37. doi: 10.1016/0735-6757(84)90107-4. [PMID: 6440569]
  • B Sandhagen, T Wegener, A Hägg. Blood viscosity, finger systolic pressure and effect of dazoxiben treatment in primary vasospastic disease. Upsala journal of medical sciences. 1984; 89(3):213-9. doi: 10.3109/03009738409179501. [PMID: 6393521]
  • A K Pedersen, M L Watson, G A FitzGerald. Inhibition of thromboxane biosynthesis in serum: limitations of the measurement of immunoreactive 6-keto-PGF1 alpha. Thrombosis research. 1984 Jan; 33(1):99-103. doi: 10.1016/0049-3848(84)90159-2. [PMID: 6546456]
  • J A Oates, A Brash, G Fitzgerald. Comparison of the effects of selective inhibition of thromboxane synthase with those of inhibition of the cyclooxygenase enzyme in man. Transactions of the American Clinical and Climatological Association. 1984; 95(?):157-62. doi: NULL. [PMID: 6433527]
  • K A Jørgensen, E Kemp, P Barfort, H Starklint, S Larsen, P H Petersen, J B Knudsen. The survival of pig to rabbit renal xenografts during inhibition of thromboxane synthesis. Thrombosis research. 1983 Dec; 32(6):585-91. doi: 10.1016/0049-3848(83)90060-9. [PMID: 6364449]
  • J Dale, E Thaulow, E Myhre, J Parry. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. Thrombosis and haemostasis. 1983 Oct; 50(3):703-6. doi: NULL. [PMID: 6689091]
  • E Thaulow. Platelet function in blood from the coronary sinus in patients with arteriosclerotic heart disease. Thrombosis and haemostasis. 1983 Oct; 50(3):629-32. doi: NULL. [PMID: 6228029]
  • G A FitzGerald, A R Brash, J A Oates, A K Pedersen. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. The Journal of clinical investigation. 1983 Oct; 72(4):1336-43. doi: 10.1172/jci111089. [PMID: 6355181]
  • E D Maguire, R B Wallis. In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat. Thrombosis research. 1983 Oct; 32(1):15-27. doi: 10.1016/0049-3848(83)90150-0. [PMID: 6689221]
  • R Winn, J Harlan, B Nadir, L Harker, J Hildebrandt. Thromboxane A2 mediates lung vasoconstriction but not permeability after endotoxin. The Journal of clinical investigation. 1983 Sep; 72(3):911-8. doi: 10.1172/jci111062. [PMID: 6886010]
  • R M Muccitelli, R R Osborn, B M Weichman. Effect of inhibition of thromboxane production on the leukotriene D4-mediated bronchoconstriction in the guinea pig. Prostaglandins. 1983 Aug; 26(2):197-206. doi: 10.1016/0090-6980(83)90088-6. [PMID: 6689082]
  • R R Garcia-Szabo, M B Peterson, W D Watkins, R Bizios, D L Kong, A B Malik. Thromboxane generation after thrombin. Protective effect of thromboxane synthetase inhibition on lung fluid balance. Circulation research. 1983 Aug; 53(2):214-22. doi: 10.1161/01.res.53.2.214. [PMID: 6684001]
  • P V Halushka, J A Cook, W C Wise. Beneficial effects of UK 37248, a thromboxane synthetase inhibitor, in experimental endotoxic shock in the rat. British journal of clinical pharmacology. 1983; 15 Suppl 1(?):133S-139S. doi: 10.1111/j.1365-2125.1983.tb02124.x. [PMID: 6337604]
  • J Harlan, R Winn, J Hildebrandt, L Harker. Selective inhibition of thromboxane synthesis during experimental endotoxemia in the goat: effects on pulmonary haemodynamics and lung lymph flow. British journal of clinical pharmacology. 1983; 15 Suppl 1(?):123S-126S. doi: 10.1111/j.1365-2125.1983.tb02122.x. [PMID: 6337602]
  • I Hutton, A C Tweddel, A C Rankin, I D Walker, J F Davidson. Effects of dazoxiben on transcardiac thromboxane levels and haemodynamics in coronary heart disease. British journal of clinical pharmacology. 1983; 15 Suppl 1(?):79S-82S. doi: 10.1111/j.1365-2125.1983.tb02113.x. [PMID: 6681709]
  • J J Belch, J Cormie, P Newman, M McLaren, J Barbenel, H Capell, P Leiberman, C D Forbes, C R Prentice. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial. British journal of clinical pharmacology. 1983; 15 Suppl 1(?):113S-116S. doi: 10.1111/j.1365-2125.1983.tb02119.x. [PMID: 6337601]
  • S Heptinstall, S C Fox. Human blood platelet behaviour after inhibition of thromboxane synthetase. British journal of clinical pharmacology. 1983; 15 Suppl 1(?):31S-37S. doi: 10.1111/j.1365-2125.1983.tb02104.x. [PMID: 6401998]
  • E W Jones, S R Cockbill, A J Cowley, S P Hanley, S Heptinstall. Effects of dazoxiben and low-dose aspirin on platelet behaviour in man. British journal of clinical pharmacology. 1983; 15 Suppl 1(?):39S-44S. doi: 10.1111/j.1365-2125.1983.tb02105.x. [PMID: 6401999]
  • M Goldman, C Hall, R J Hawker, C N McCollum. Dazoxiben examined for platelet inhibitory effect in an artificial circulation. British journal of clinical pharmacology. 1983; 15 Suppl 1(?):61S-65S. doi: 10.1111/j.1365-2125.1983.tb02109.x. [PMID: 6681706]
  • S J Coker, J R Parratt. Effects of dazoxiben on arrhythmias and ventricular fibrillation induced by coronary artery occlusion and reperfusion in anaesthetised greyhounds. British journal of clinical pharmacology. 1983; 15 Suppl 1(?):87S-95S. doi: 10.1111/j.1365-2125.1983.tb02115.x. [PMID: 6681710]
  • S E Burke, A M Lefer, G M Smith, J B Smith. Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor. British journal of clinical pharmacology. 1983; 15 Suppl 1(?):97S-101S. doi: 10.1111/j.1365-2125.1983.tb02116.x. [PMID: 6681711]
  • N J Dodd, M P Gordge, M J Weston. Use of a thromboxane synthetase inhibitor, dazoxiben, during haemodialysis. British journal of clinical pharmacology. 1983; 15 Suppl 1(?):67S-70S. doi: 10.1111/j.1365-2125.1983.tb02110.x. [PMID: 6337605]